Kiniksa Pharmaceuticals International Quarterly Income Statement
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International revenue and earnings
In the quarter ended Mar 31, 2026, Kiniksa Pharmaceuticals International generated $214.3 million in revenue, up 55.5% from the same quarter a year earlier. Net income was $22.6 million (+164.6% year over year), for a net margin of 10.5% versus a median of 7.0% in the prior 5 quarters. Gross margin was 90.3% (up from 87.0%) and operating margin 13.7%.
Diluted earnings per share came in at $0.27, up from $0.11.
Summary generated from market data by MetaCap's automated system. Methodology
Kiniksa Pharmaceuticals International income statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 214.27M | 202.13M | 180.85M | 156.80M | 137.78M | 122.54M | 112.21M | 108.63M | 79.86M | 83.39M | 67.05M | 71.47M |
| Revenue growth (YoY) | +55.51% | +64.95% | +61.17% | +44.34% | +72.54% | +46.93% | +67.37% | +51.99% | +65.18% | +34.76% | -32.37% | +164.99% |
| Cost of Revenue | 20.80M | 20.95M | 20.26M | 18.60M | 17.87M | 17.90M | 20.11M | 12.32M | 10.58M | 9.58M | 9.09M | 7.70M |
| Gross Profit | 193.47M | 181.18M | 160.60M | 138.19M | 119.92M | 104.64M | 92.11M | 96.31M | 69.28M | 73.81M | 57.96M | 63.77M |
| Operating Expenses | 164.20M | 161.41M | 136.58M | 118.03M | 106.64M | 123.94M | 101.76M | 96.43M | 85.82M | 73.73M | 68.89M | 66.93M |
| Research & Development | 27.48M | 34.61M | 24.17M | 18.75M | 19.32M | 35.22M | 26.06M | 24.02M | 26.33M | 20.05M | 17.11M | 23.77M |
| Selling, General & Admin | 61.15M | 56.77M | 49.10M | 46.86M | 43.53M | 40.53M | 46.40M | 42.40M | 38.68M | 36.74M | 34.47M | 29.18M |
| Operating Income | 29.27M | 19.77M | 24.02M | 20.16M | 13.27M | -19.30M | -9.66M | -117.00K | -16.54M | 81.00K | -10.93M | -3.15M |
| Other Income (Expense) | 3.41M | 3.50M | 3.14M | 2.72M | 2.29M | 2.32M | 2.46M | 2.42M | 2.27M | 2.37M | 2.43M | 1.92M |
| Pretax Income | 32.68M | 23.27M | 27.16M | 22.88M | 15.56M | -16.98M | -7.20M | 2.30M | -14.28M | 2.45M | -8.50M | -1.24M |
| Income Tax | 10.09M | 9.07M | 8.72M | 5.04M | 7.03M | -8.09M | 5.49M | 6.21M | 3.43M | -22.79M | 5.36M | -16.21M |
| Net Income | 22.59M | 14.20M | 18.43M | 17.83M | 8.54M | -8.89M | -12.69M | -3.91M | -17.70M | 25.24M | -13.86M | 14.97M |
| Net Income growth (YoY) | +164.57% | — | — | — | — | -135.22% | — | -126.10% | — | +465.73% | -106.18% | — |
| EPS (Basic) | 0.30 | 0.19 | 0.25 | 0.24 | 0.12 | -0.11 | -0.18 | -0.06 | -0.25 | 0.37 | -0.20 | 0.21 |
| EPS (Diluted) | 0.27 | 0.18 | 0.23 | 0.23 | 0.11 | -0.11 | -0.18 | -0.06 | -0.25 | 0.37 | -0.20 | 0.21 |
| Shares Outstanding (Basic) | 76.52M | — | 74.71M | 73.44M | 72.65M | — | 71.73M | 71.00M | 70.63M | — | 70.19M | 69.92M |
| Shares Outstanding (Diluted) | 82.41M | — | 80.04M | 77.94M | 76.15M | — | 71.73M | 71.00M | 70.63M | — | 70.19M | 71.63M |
| EBITDA | 29.73M | 20.23M | 24.41M | 20.52M | 13.62M | -18.90M | -9.26M | 313.00K | -16.08M | 621.00K | -10.32M | -2.55M |
| Gross Margin | 90.29% | 89.64% | 88.80% | 88.14% | 87.03% | 85.40% | 82.08% | 88.66% | 86.75% | 88.51% | 86.45% | 89.23% |
| Operating Margin | 13.66% | 9.78% | 13.28% | 12.86% | 9.63% | -15.75% | -8.61% | -11.00% | -20.71% | 10.00% | -16.30% | -4.41% |
| Net Margin | 10.54% | 7.02% | 10.19% | 11.37% | 6.20% | -7.25% | -11.31% | -3.60% | -22.17% | 30.26% | -20.66% | 20.95% |
This table shows 12 quarterly periods of Kiniksa Pharmaceuticals International's income statement, from Q1 2026 back to Q2 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow KNSA's reporting calendar. What is a income statement?